OssDsign reaches commercial milestone of 200 implants in France
Uppsala, March 14 2023. OssDsign AB (publ.) today announces that the company has reached the commercial milestone of 200 implants in France. Since entering the market in late 2019, OssDsign has signed several important tenders in France leading to significantly accelerated sales during the last year.
In 2019, the French health authorities decided OssDsign Cranial PSI provided high therapeutic value to patients and granted the product reimbursement on the French market. During the following years, OssDsign established an initial sales presence, secured first sales, and later gained broader market access by winning numerous tenders, including the most prestigious win to date of the long-term contract with the largest hospital network, Assistance Publique – Hopitaux de Paris (AP-HP). In early 2022, OssDsign decided to further increase focus on France and restructured its commercial presence accordingly, leading to solid sales acceleration in the second half of 2022 - ultimately allowing the company to reach the 200 implant milestone within only a few years.
“This commercial milestone highlights the speed of which we have established OssDsign Cranial PSI in France, turning the French market into a solid business and growth platform with major tenders secured and many recurring users - all during a three-year period strongly influenced by a pandemic. We have therefore clearly demonstrated that by combining a highly differentiated technology offering with a focused go-to-market model, we have a recipe for future growth,” said Morten Henneveld, CEO of OssDsign.
OssDsign Cranial PSI is a patient-specific cranial implant made from 3D printed medical-grade titanium covered by a regenerative calcium phosphate composition. While the titanium skeleton reinforces the implant and resists physical and mechanical stress, the unique calcium phosphate composition provides healing and regenerative properties, allowing regrowth of the patient's own bone. Over time, the calcium phosphate composition degrades and is replaced with bone, leaving the patient with a well-integrated implant, potentially lasting a lifetime.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: [email protected]
Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: [email protected]
About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
